vimarsana.com
Home
Live Updates
Werth Family Investment Associates Converts Remaining $3.3M
Werth Family Investment Associates Converts Remaining $3.3M
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into ...
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build
Related Keywords
United States ,
Kansas City ,
Kansas ,
Thomas Dalton ,
Matt Kreps ,
Peterj Werth ,
Darrow Associates ,
Nasdaq ,
Securities Exchange ,
Exchange Commission ,
Platform Technology ,
Werth Family Investment Associates ,
Cingulate Therapeutics Llc Ctx ,
Cingulate Inc ,
Precision Timed Release ,
Cingulate Therapeutics ,
Note Conversion Agreement ,
Pre Funded Warrants ,
Securities Act ,
Hyperactivity Disorder ,
Erosion Barrier Layer ,
Looking Statements ,
Securities Exchange Act ,
Annual Report ,
Public Relations ,
Region ,